Gracell Biotechnologies Appoints Seasoned Gene & Cell Therapy Executive Dr. Jenny (Yajin) Ni as Chief Technology Officer

SUZHOU and SHANGHAI, China, May 11, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the appointment of Dr. Jenny (Yajin) Ni as its Chief Technology Officer (CTO). In her role, Dr. Ni will be responsible for strategically leading CAR-T product development, Chemistry, Manufacturing, and Control (CMC), and supply chain management activities. Dr. Ni will lead the efforts to ensure the smooth technology transfer to Gracell's strategic collaborator, Lonza, for manufacturing of FasTCAR-enabled product candidates in the U.S.

Dr. Ni brings over 25 years of experience in process and product development for gene & cell therapies and vaccines to Gracell. Prior to joining Gracell, Dr. Ni served as Head of Process Development at both Pfizer and Allogene Therapeutics, where she served in senior leadership roles in technical development and operation functions, led allogeneic CAR-T product development, and advanced multiple first-in-human allogeneic CAR-T pipeline programs through preclinical to clinical development, including five IND approvals for hematological malignancy and solid tumor indications. Prior to that, Dr. Ni also served as Director of Tech Operations at VIRxSYS Inc., where she held roles of increasing responsibility across process and analytical development, technology transfer, as well as technical support for GMP manufacturing and QC testing. While at VIRxSYS, Dr. Ni was instrumental in bringing the first-ever lentiviral vector-modified autologous T cell product for HIV infection into clinical development. Dr. Ni holds a Ph.D. in Molecular Virology from Kyoto University in Japan and an M.D. in Internal Medicine from Kunming Medical University in China.

"We are delighted that Dr. Ni has joined Gracell as CTO," said Dr. William (Wei) Cao. "Manufacturing is often a critical bottleneck in developing and commercializing CAR-T therapies. With the establishment of an internal GMP-compliant manufacturing facility in Suzhou and a process development center in Shanghai, we are well-positioned to support our extensive pipeline. A key component of our manufacturing strategy is a fully-closed systemthat enables us to substantially reduce costs, improve productivity, and scale-up production of our autologous FasTCAR product candidates. With Dr. Ni's extensive knowledge and experience, I am confident that Gracell will further accelerate the expansion of its global manufacturing capability and enhance our leadership position within the cell and gene therapy field."

"Gracell has successfully built a GMP-compliant manufacturing facility and an R&D center in China, as well as started establishing a state-of-the-art cGMP process in the U.S. in collaboration with Lonza. Gracell's comprehensive manufacturing strategy serves as a great foundation for its preclinical and clinical development initiatives," said Dr. Jenny (Yajin) Ni. "As CTO, I am excited to lead our efforts to ensure the smooth transfer of our pioneering FasTCAR technology to Lonza, and continuously broaden our proprietary genetic engineering and cell manufacturing capabilities and advance the next generation of CAR-T cell therapies for the treatment of cancer."

About Gracell

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com.
Follow @GracellBio on LinkedIn.

Cautionary Noted Regarding Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing date of the offering. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the section entitled "Risk Factors" in Gracell's most recent annual report on Form 20-F as well as discussions of potential risks, uncertainties, and other important factors in Gracell's subsequent filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Gracell specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Readers should not rely upon the information on this page as current or accurate after its publication date.

Media contact
Marvin Tang
marvin.tang@gracellbio.com

Investor contact
Gracie Tong
gracie.tong@gracellbio.com

Tags:
Look out for further updates on our Facebook fan page!

Related Articles

  • 【政府工略】1823助理客戶服務主管人工高?月薪$21,810 只須中學學歷

    當網絡未發達時,香港人有任何問題都會打1823查詢,所需政府部門效率促進辦公室曾公布香港人最常問的10個熱門問題,例如「僱員放病假,有醫生紙是否如常支薪」、「如何申請國際駕駛許可證」、「如何報名參加康文署體育活動」等等。雖然大家現時可透過網絡解決即時的問題,可是1823仍然為港人服務,包括推出網站及手機應用程式,讓有需要的市民查詢。最近,效率促進辦公室為1823招聘助理客戶服務主管,月薪18,450至$21,810,以非公務員條塊聘用,合約期一年。

  • 【政府工略】文科生福音!發展局請助理文物主任 月薪$23,415

    很多人認為讀商科、理科,長大後的職涯發展會較理想,尤其入讀所謂「神科」,賺錢能力遠遠拋離其他科目。不過,政府發展局最近招聘的助理文物主任,正正是文科生的福音,只要你在大學主修以下的科目即可申請,月薪$23,415。

  • 【政府工略】政府請法官官邸家務助理 無學歷要求 月薪$20,000

    大多人以為政府工多文職工,其實各部門定時都會招聘非文職及入職要求較低的工作,就如最近司法機構為終審法院首席法官官邸聘請的家務助理,以非公務員合約條款騁用,無學歷要求,只要符合以下條件即可申請。

  • 【職場熱話】扮孫悟空被餵食5小時 網民:最理想工作!下個月可以扮OOO!

    不少打工仔都在找尋一份夢寐以求的荀工!可是,怎樣才算一份荀工呢?不用太用腦?可以經常發夢?人工的足夠生活?可以養活自己?食得飽?咦?似乎有一份工非常符合「荀工」的條件呢!

  • 【政府工略】律政司請法律書記 中學畢業月薪$21,340

    有關法律的工作,一般人以為必定要有法律背景的求職者,方能合資格申請。不過,律政司招聘的政府工 — 合約法律書記,不需要任何法律背景,只要符合以下入職條件即可報名,月薪$21,340。

  • 【職場測驗】Fresh Grad搵工必睇!10條問題測出你最適合入邊行

    俗語有云「女怕嫁錯郎,男怕入錯行」,對於準備投身社會的Fresh Grad來說,現在最重要的是認清楚的求職方向,為未來的事業發展打下良好基礎。如果你正處於搵工迷惘階段,不妨回答以下心理測驗的10條問題,再將分數加起來,看看自己最適合從事哪個行業吧!

  • 【政府工略】民政署時薪$120請助理 負責社區強制檢測

    香港出現新冠肺炎變種病毒株,為切斷社區傳播鏈,政府先後將多區地區或樓宇,列為受限區域,範圍內受檢人士則須留在處所接受強制檢測。由於多個地區都需要列入強制檢測公告,政府需要大量人手應付需求,民政事務總署最近為離島民政事務處,招聘兼職非公務員合約行動助理(強制檢測公告/限制與檢測宣告),時薪$120,入職要求不高,有意尋找兼職工作的打工仔,可於2021年5月12日前申請。

  • 【行業辛酸】12碼保安大呻返工日日被監視 業主計時巡樓、限時去廁所、唔畀㩒電話

    疫情打擊就業,間接令保安員成為熱門職業,不論男女老幼都有興趣申領保安牌旁身。雖然保安的工作看似簡單輕鬆,不過當中也有不少難處。最近有保安從業員向我們分享工作辛酸,他指每日都被業主立案法團成員監視,不但陪他坐足12小時,更在他巡樓及去廁所時計時倒數,令他感到十分煩擾。

  • 【職場熱話】人工得8千但返工好開心 員工:每日淨係數鉛筆、冇是非

    很現實,薪金一定是大多數打工仔考慮一份工作的首要條件。但其實工作上的滿足感和愉悅程度,對於打工仔的身心靈健康都很重要。你現在返工,開心嗎?

  • 【職場熱話】移民澳洲太輕鬆竟然唔適應? 打工仔:係咪做奴工做得太耐?

    社會運動加上疫情之下,大家都為日後的生活多了思考和打算,不少人都計劃移民,希望可以有更好的生活空間。不過,香港打工仔們,又可以適應外國的職場文化嗎?